Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: A retrospective, observational, sequential cohort analysis

Clinical Therapeutics

Volumn 32, Issue 4, 2010, Pages 637-648

  Kubiak, David W ^a   Bryar, Julie M ^a,b   McDonnell, Anne M ^a   Delgado Flores, Jorge O ^a   Mui, Emily ^a   Baden, Lindsey R ^a,c,d   Marty, Francisco M ^a,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Caspofungin; Echinocandins; Febrile neutropenia; Hematologic malignancy; Invasive fungal disease; Micafungin

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ADULT; ANAPHYLAXIS; ARTICLE; ASPERGILLOSIS; CANDIDEMIA; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PATIENT SELECTION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; WHEEZING;

ADULT; AGED; ANTIFUNGAL AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; FEVER; HUMANS; LIPOPEPTIDES; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77952540915     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.04.005     Document Type: Article

References (26)

1. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751.
2. Vartivarian SE, Anaissie EJ, Bodey GP Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis, and management. Clin Infect Dis 1993, 17(Suppl 2):S487-S491.
3. Schuler U, Bammer S, Aulitzky WE, et al. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie 2007, 30:185-191.
4. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999, 340:764-771. for the National Institute of Allergy and Infectious Diseases Mycoses Study Group.
5. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever [published correction appears in N Engl J Med. 2007;356:760]. N Engl J Med 2002, 346:225-234. for the National Institute of Allergy and Infectious Diseases Mycoses Study Group.
6. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351:1391-1402.
7. Wingard JR, White MH, Anaissie E, et al. A randomized, doubleblind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000, 31:1155-1163. for the L Amph/ABLC Collaborative Study Group.
8. Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000, 108:282-289.
9. Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006, 43(Suppl 1):S28-S39.
10. Marchetti O, Cordonnier C, Calandra T Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer Suppl 2007, 5:32-42.
11. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: Six years of global surveillance [published correction appears in J Clin Microbiol. 2008;46:3184-3185]. J Clin Microbiol 2008, 46:150-156.
12. Cancidas (caspofungin acetate) [prescribing information]. March 30, 2010, Accessed. http://www.merck.com/product/usa/pi_circulars/c/cancidas/cancidas_pi.pdf.
13. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005, 49:3317-3324.
14. Toubai T, Tanaka J, Ota S, et al. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med 2007, 46:3-9.
15. Yanada M, Kiyoi H, Murata M, et al. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 2006, 45:259-264.
16. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet 2007, 369:1519-1527. for the Micafungin Invasive Candidiasis Working Group.
17. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis [published correction appears in Clin Infect Dis. 2008;47:302]. Clin Infect Dis 2007, 45:883-893.
18. Lewis JS, Jorgensen JH, Patterson JE Clinical and financial impact of adoption of micafungin as the preferred echinocandin in a university teaching hospital. Presented at: 44th Annual Meeting of the Infectious Diseases Society of America 2006, Toronto, Canada. Abstract 573.
19. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177. for the Infectious Diseases Society of America, Society for Healthcare Epidemiology of AmericaSociety for Healthcare Epidemiology of America.
20. de Pauw BE, Sable CA, Walsh TJ, et al. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: Analysis of results from the Caspofungin Empirical Therapy Study. Transpl Infect Dis 2006, 8:31-37.
21. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821. for the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupNational Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
22. Rothman KJ, Greenland S, Lash TL Modern Epidemiology 2008, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, Pa. 3rd ed.
23. Sucher AJ, Chahine EB, Balcer HE Echinocandins: The newest class of antifungals. Ann Pharmacother 2009, 43:1647-1657.
24. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002, 34:7-14. for the Invasive Funcal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer, Mycoses Study Group of the National Institute of Allergy and Infectious DiseasesMycoses Study Group of the National Institute of Allergy and Infectious Diseases.
25. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006, 25:1110-1115.
26. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005, 49:4536-4545.